Lye Theng Lock
About Lye Theng Lock
Lye Theng Lock serves as the Head of Allogeneic Process Development at Kite Pharma, a position he has held since 2021. He has a background in chemical and biological engineering, with experience in various roles at institutions such as the State University of New York at Buffalo, RoosterBio Inc., Atara Biotherapeutics, and Lonza.
Work at Kite Pharma
Lye Theng Lock currently serves as the Head of Allogeneic Process Development at Kite Pharma. In this role, he oversees the development of allogeneic therapies, focusing on optimizing processes to enhance product efficiency and effectiveness. His leadership contributes to Kite Pharma's mission of advancing innovative cancer therapies.
Previous Experience in Biotech
Before joining Kite Pharma, Lye Theng Lock held several significant positions in the biotechnology sector. He worked as a Director of Process & Product Development at RoosterBio Inc. from 2016 to 2018, and as a Director of Process Development at Atara Biotherapeutics from 2018 to 2021. His experience spans various roles that emphasize process optimization and product development in the field.
Education and Expertise
Lye Theng Lock earned a PhD in Chemical & Biological Engineering from the University at Buffalo, where he studied from 2005 to 2010. His educational background provides a strong foundation for his expertise in process development and engineering within the biotechnology industry.
Research and Academic Roles
Lye Theng Lock began his career in academia at the State University of New York at Buffalo, where he worked as a Research Assistant from 2005 to 2010 and as a Teaching Assistant from 2005 to 2007. These roles allowed him to develop research skills and gain experience in teaching and mentoring students in engineering disciplines.
Career Progression in Biotechnology
Lye Theng Lock's career in biotechnology includes significant roles at Lonza as a Scientist from 2011 to 2014 and at RoosterBio Inc. as a Senior Manager from 2014 to 2016. His career trajectory reflects a consistent focus on advancing bioprocessing and product development, contributing to the growth of the organizations he has been part of.